Bone biology, signaling pathways, and therapeutic targets for osteoporosis

Maturitas

Volumn 82, Issue 2, 2015, Pages 245-255

  Iñiguez Ariza, Nicole M ^a   Clarke, Bart L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anti Dickkopf antibody; Anti sclerostin antibody; Cathepsin K inhibitors; Osteoporosis; PTH; PTHrP

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACTIVIN A; BISPHOSPHONIC ACID DERIVATIVE; BLOSOZUMAB; BONE MORPHOGENETIC PROTEIN; CATHEPSIN K; CATHEPSIN K INHIBITOR; DENOSUMAB; GELATINASE; GELATINASE B; GLYCERYL TRINITRATE; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; RALOXIFENE; ROMOSOZUMAB; STRONTIUM RANELATE; BONE DENSITY CONSERVATION AGENT;

BONE CHARACTERISTICS AND FUNCTIONS; BONE MATRIX; BONE MINERALIZATION; BONE REMODELING; BONE STRENGTH; HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; OSTEOPROGENITOR CELL; REVIEW; SIGNAL TRANSDUCTION; TRABECULAR BONE; WNT SIGNALING PATHWAY; DRUG EFFECTS; OSTEOPOROSIS, POSTMENOPAUSAL;

BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DENOSUMAB; DIPHOSPHONATES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; SIGNAL TRANSDUCTION; TERIPARATIDE;

EID: 84942824156     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2015.07.003     Document Type: Review

References (88)

1. S. Kobayashi, H.E. Takahashi, A. Ito, N. Saito, M. Nawata, H. Horiuchi, and et al. Trabecular minimodeling in human iliac bone Bone 32 2003 163 169
2. Y. Ubara, T. Tagami, S. Nakanishi, N. Sawa, J. Hoshino, T. Suwabe, and et al. Significance of minimodeling in dialysis patients with adynamic bone disease Kidney Int. 68 2005 833 839
3. Y. Ubara, T. Fushimi, T. Tagami, N. Sawa, J. Hoshino, M. Yokota, and et al. Histomorphometric features of bone in patients with primary and secondary hyperparathyroidism Kidney Int. 63 2003 1809 1816
4. R. Lindsay, F. Cosman, H. Zhou, M. Bostrom, V. Shen, J. Cruz, and et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest biopsy: early actions of teriparatide J. Bone Miner. Res. 21 2006 366 373
5. D.B. Burr Targeted and nontargeted remodeling Bone 30 2002 2 4
6. A.M. Parfitt Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression Bone 30 2002 5 7
7. G.D. Roodman Cell biology of the osteoclast Exp. Hematol. 27 1999 1229 1241
8. W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342
9. H.C. Blair, and N.A. Athanasou Recent advances in osteoclast biology and pathological bone resorption Histol. Histopathol. 19 2004 189 199
10. I.A. Silver, R.J. Murrills, and D.J. Etherington Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts Exp. Cell Res. 175 1988 266 276
11. J.M. Delaisse, T.L. Andersen, M.T. Engsig, K. Henriksen, T. Troen, and L. Blavier Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclast activities Microsc. Res. Tech. 61 2003 504 513
12. E.F. Eriksen Normal and pathological remodeling of human trabecular bone: three-dimensional reconstruction of the remodeling sequence in normals and metabolic bone disease Endocr. Rev. 7 1986 379 408
13. S.V. Reddy Regulatory mechanisms operative in osteoclasts Crit. Rev. Eukaryot. Gene Expr. 14 2004 255 270
14. L. Bonewald, and G.R. Mundy Role of transforming growth factor beta in bone remodeling Clin. Orthop. Relat. Res. 2S 1990 35 40
15. J.M. Hock, M. Centrella, and E. Canalis Insulin-like growth factor I (IGF-I) has independent effects on bone matrix formation and cell replication Endocrinology 122 2004 254 260
16. R.M. Locklin, R.O. Oreffo, and J.T. Triffitt Effects of TGFbeta and bFGF on the differentiation of human bone marrow stromal fibroblasts Cell Biol. Int. 23 1999 185 194
17. T.J. Martin, and N.A. Sims Osteoclast-derived activity in the coupling of bone formation to resorption Trends Mol. Med. 11 2005 76 81
18. T.H. Smit, E.H. Burger, and J.M. Huyghe Is BMU-coupling a strain-regulated phenomenon? A finite element analysis J. Bone Miner. Res. 15 2000 301 307
19. T.H. Smit, E.H. Burger, and J.M. Huyghe A case for strain-induced fluid flow as a regulator of BMU-coupling and osteonal alignment J. Bone Miner. Res. 17 2002 2021 2029
20. H.C. Anderson Matrix vesicles and calcification Curr. Rheumatol. Rep. 5 2003 222 226
21. E.H. Burger, J. Klein-Nuland, and T.H. Smit Strain-derived canalicular fluid flow regulates osteoclast activity in a remodeling osteon - a proposal J. Biomech. 36 2003 1452 1459
22. H. Dobnig, and R.T. Turner Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells Endocrinology 136 1995 3632 3638
23. E.M. Hauge, D. Qvesel, E.F. Eriksen, L. Mosekilde, and F. Melsen Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers J. Bone Miner. Res. 16 2001 1575 1582
24. A.M. Parfitt Osteonal and hemiosteonal remodeling: the spatial and temporal framework for signal traffic in adult bone J. Cell Biochem. 55 1994 273 276
25. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342
26. S.L. Teitelbaum, and F.P. Ross Genetic regulation of osteoclast development and function Nat. Rev. Genet. 4 2003 638 649
27. M.M. Cohen Jr. The new bone biology: pathologic, molecular, and clinical correlates Am. J. Med. Genet. A 140 2006 2646 2706
28. F.P. Ross, and S.L. Teitelbaum αvβ3 and macrophage colony-stimulating factor: partners in osteoclast biology Immunol. Rev. 208 2005 88 105
29. S.L. Teitelbaum, Y. Abu-Amer, and F.P. Ross Molecular mechanisms of bone resorption J. Cell Biochem. 59 1995 1 10
30. H.K. Vaananen, H. Zhao, M. Mulari, and J.M. Halleen The cell biology of osteoclast function J. Cell Sci. 113 2000 377 381
31. M.F. Pittenger, A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, and et al. Multilineage potential of adult human mesenchymal stem cells Science 284 1990 143 147
32. M.J. Doherty, B.A. Ashton, S. Walsh, J.N. Beresford, M.E. Grant, and A.E. Canfield Vascular pericytes express osteogenic potential in vitro and in vivo J. Bone Miner. Res. 13 1998 828 838
33. C.Y. Logan, and R. Nusse The Wnt signaling pathway in development and disease Annu. Rev. Cell Dev. Biol. 20 2004 781 810
34. L.M. Boyden, J. Mao, J. Belsky, L. Mitzner, A. Farhi, M.A. Mitnick, and et al. High bone density due to a mutation in LDL receptor-related protein 5 N. Engl. J. Med. 346 2002 1513 1521
35. R.D. Little, R.R. Recker, and M.L. Johnson High bone density due to a mutation in LDL receptor-related protein 5 N. Engl. J. Med. 347 2002 943 944
36. C.S. Shin, F. Lecanda, S. Sheikh, L. Weitzmann, S.L. Cheng, and R. Civitelli Relative abundance of different cadherins defines differentiation of mesenchymal precursors into osteogenic, myogenic, or adipogenic pathways J. Cell Biochem. 78 2000 566 577
37. S.R. Cummings, and L.J. Melton Epidemiology and outcomes of osteoporotic fractures Lancet 359 9319 2002 1761 1767
38. A.N. Tosteson, and C.S. Hammond Quality of life assessment in osteoporosis: health-status and preference-based measures Pharmacogenomics 20 2002 289 303
39. N.M. Appelman-Dijkstra, and S.E. Papapoulos Novel approaches to the treatment of osteoporosis Best Pract. Res. Clin. Endocrinol. Metab. 28 2014 843 857
40. R.G. Russell Bisphosphonates: the first 40 years Bone 49 2011 2 19
41. S. Zaheer, M. LeBoff, and E.M. Lewiecki Denosumab for the treatment of osteoporosis Expert Opin. Drug Metab. Toxicol. 11 2015 461 470
42. F. Lecaille, D. Bromme, and G. Lalmanach Biochemical properties and regulation of cathepsin K activity Biochimie 90 2008 208 226
43. F. Cosman, E.F. Eriksen, C. Recknor, P.D. Miller, N. Guañabens, C. Kasperk, and et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis J. Bone Miner. Res. 26 2011 503 511
44. M.J. Horwitz, M. Augustine, L. Kahn, E. Martin, C.C. Oakley, R.M. Carneiro, and et al. A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP Study J. Bone Miner. Res. 28 2013 2266 2276
45. R. Baron, and M. Kneissel WNT signaling in bone homeostasis and disease: from human mutations to treatments Nat. Med. 19 2013 179 192
46. K.E. Poole, R.L. van Bezooijen, N. Loveridge, H. Hamersma, S.E. Papapoulos, C.W. Löwik, and et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation FASEB J. 19 2005 1842 1844
47. D.G. Winkler, M.K. Sutherland, J.C. Geoghegan, C. Yu, T. Hayes, J.E. Skonier, and et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist EMBO J. 22 2003 6267 6276
48. R.L. van Bezooijen, B.A. Roelen, A. Visser, L. van der Wee-Pals, E. de Wilt, M. Karperien, and et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist J. Exp. Med. 199 2004 805 814
49. A.R. Wijenayaka, M. Kogawa, H.P. Lim, L.F. Bonewald, D.M. Findlay, and G.J. Atkins Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway PLoS One 6 2011 e25900
50. R.L. van Bezooijen, J.P. Svensson, D. Eefting, A. Visser, G. van der Horst, M. Karperien, and et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation J. Bone Miner. Res. 22 2007 19 28
51. X. Li, Y. Zhang, H. Kang, W. Liu, P. Liu, J. Zhang, and et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling J. Biol. Chem. 280 2005 19883 19887
52. M. Semenov, K. Tamai, and X. He SOST is a ligand for LRP5/6 and a Wnt signaling inhibitor J. Biol. Chem. 280 2005 26770 26775
53. A.G. Robling, P.J. Niziolek, L.A. Baldridge, K.W. Condon, M.R. Allen, I. Alam, and et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin J. Biol. Chem. 283 2008 5866 5875
54. H.Z. Ke, W.G. Richards, X. Li, and M.S. Ominsky Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases Endocr. Rev. 33 2012 747 783
55. P. Clement-LaCroix, M. Ai, F. Morvan, S. Roman-Roman, B. Vayssière, C. Belleville, and et al. Lrp5 independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice Proc. Natl. Acad. Sci. U. S. A. 102 2005 17406 17411
56. S. Lotinun, R.S. Pearsall, W.C. Horne, and R. Baron Activin receptor signaling: a potential therapeutic target for osteoporosis Curr. Mol. Pharmacol. 5 2012 195 204
57. S.A. Jamal, C.J. Hamilton, R. Eastell, and S.R. Cummings Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial JAMA 305 2011 800 807
58. S. Boonen, E. Rosenberg, F. Claessens, D. Vanderschueren, and S. Papapoulos Inhibition of cathepsin K for treatment of osteoporosis Curr. Osteop. Rep. 10 2012 73 79
59. A.G. Costa, N.E. Costano, B.C. Silva, S. Cremers, and J.P. Bilezikian Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis Nat. Rev. Rheumatol. 7 2011 447 456
60. J.A. Eisman, H.G. Bone, D.J. Hosking, M.R. McClung, I.R. Reid, R. Rizzoli, and et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect J. Bone Miner. Res. 26 2011 242 251
61. H.G. Bone, M.R. McClung, C. Roux, R.R. Recker, J.A. Eisman, N. Verbruggen, and et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density J. Bone Miner. Res. 25 2010 937 947
62. S.A. Stoch, S. Zajic, J. Stone, D.L. Miller, K. Van Dyck, M.J. Gutierrez, and et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies Clin. Pharmacol. Ther. 86 2009 175 182
63. T. Cusick, C.M. Chen, B.L. Pennypacker, M. Pickarski, D.B. Kimmel, B.B. Scott, and et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey J. Bone Miner. Res. 27 2012 524 537
64. P.J. Masarachia, B.L. Pennypacker, M. Pickarski, K.R. Scott, G.A. Wesolowski, S.Y. Smith, and et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys J. Bone Miner. Res. 27 2012 509 523
65. S. Nagase, M. Ohyama, Y. Hashimoto, M. Small, T. Kuwayama, and S. Deacon Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study J. Clin. Pharmacol. 52 2012 306 318
66. R. Eastell, S. Nagase, M. Ohyama, M. Small, J. Sawyer, S. Boonen, and et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study J. Bone Miner. Res. 26 2011 1303 1312
67. T.M. Rünger, S. Adami, C.L. Benhamou, E. Czerwiński, J. Farrerons, D.L. Kendler, and et al. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib J. Am. Acad. Dermatol. 66 2012 e89 e96
68. R. Baron, and E. Hesse Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives J. Clin. Endocrinol. Metab. 29 2012 311 325
69. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, and et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N. Engl. J. Med. 344 2001 1434 1441
70. D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, T.F. Lang, and et al. The effects of parathyroid hormone and alendronate alone or in combination for postmenopausal osteoporosis N. Engl. J. Med. 349 2003 1207 1215
71. D.M. Black, J.P. Bilezikian, K.E. Ensrud, S.L. Greenspan, L. Palermo, T. Hue, and et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis N. Engl. J. Med. 353 2005 555 565
72. V. Subbiah, V.S. Madsen, A.K. Raymond, R.S. Benjamin, and J.A. Ludwig Of mice and men: divergent risks of teriparatide-induced osteosarcoma Osteoporos. Int. 21 2010 1041 1045
73. T. Nakamura, T. Sugimoto, T. Nakano, H. Kishimoto, M. Ito, M. Fukunaga, and et al. Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk J. Clin. Endocrinol. Metab. 97 2012 3097 3106
74. T. Ponnapakkam, R. Katikaneni, H. Suda, S. Miyata, O. Matsushita, J. Sakon, and et al. A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice Calcif. Tissue Int. 91 2012 196 201
75. T. Ponnapakkam, R. Katikaneni, E. Miller, A. Ponnapakkam, S. Hirofumi, S. Miyata, and et al. Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice Calcif. Tissue Int. 88 2011 511 520
76. S.P. Hammerle, L. Mindeholm, A. Launonen, B. Kiese, R. Loeffler, E. Harfst, and et al. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women Bone 50 2012 965 973
77. L.A. Fitzpatrick, C.E. Dabrowski, G. Cicconetti, D.N. Gordon, S. Papapoulos, H.G. Bone 3rd, and et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density J. Clin. Endocrinol. Metab. 96 2011 2441 2449
78. S. Kimura, T. Nakagawa, Y. Matsuo, Y. Ishida, Y. Okamoto, and M. Hayashi JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats Eur. J. Pharmacol. 668 2011 331 336
79. B.Z. Leder, L.S. O'Dea, J.R. Zanchetta, P. Kumar, K. Banks, K. McKay, and et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis J. Clin. Endocrinol. Metab. 100 2015 697 706
80. V. Krishnan, H.U. Bryant, and O.A. Macdougald Regulation of bone mass by Wnt signaling J. Clin. Invest. 116 2006 1202 1209
81. X. Li, M.S. Ominsky, K.S. Warmington, S. Morony, J. Gong, J. Cao, and et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis J. Bone Miner. Res. 24 2009 578 588
82. D. Padhi, G. Jang, B. Stouch, L. Fang, and E. Posvar Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody J. Bone Miner. Res. 26 2011 19 26
83. M.R. McClung, A. Grauer, S. Boonen, M.A. Bolognese, J.P. Brown, A. Diez-Perez, and et al. Romosozumab in postmenopausal women with low bone mineral density N. Engl. J. Med. 370 2014 412 420
84. R.R. Recker, C.T. Benson, T. Matsumoto, M.A. Bolognese, D.A. Robins, J. Alam, and et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density J. Bone Miner. Res. 30 2015 216 224
85. C.P. Recknor, R.R. Recker, C.T. Benson, D.A. Robins, A.Y. Chiang, J. Alam, and et al. The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density J. Bone Miner. Res. 2015 February 24 [Epub ahead of print]
86. H. Glantschnig, K. Scott, R. Hamptom, N. Wei, P. McCracken, P. Nantermet, and et al. A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody J. Pharmacol. Exp. Ther. 338 2011 568 578
87. M. Cicciu, A.S. Herford, G. Juodzbalys, and E. Stoffella Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw J. Craniofac. Surg. 23 2012 784 788
88. B. Skoglund, C. Forslund, and P. Aspenberg Simvastatin improves fracture healing in mice J. Bone Miner. Res. 17 2002 2004 2008